Remission in Rheumatoid Arthritis in the Asian-Pacific Region
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ru Li, Dr.
- Phone Number: 86-18611616251
- Email: doctorliru123@163.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- RA patients fulfilled the American College of Rheumatology 1987 criteria or the 2010 ACR/EULAR classification criteria.
- Patients aged > 18 years.
Exclusion Criteria:
- No
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
RA patients
As routinary clinical practice and observational study
|
as clinical practice
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
remission rate of RA patients in different countries in the Asian-Pacific area
Time Frame: 12-24 months
|
according to the different criteria of clinical remission in RA patients
|
12-24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PKUPH-R-RA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
NCT01480388WithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
NCT00036374CompletedRheumatoid Arthritis, Juvenile
-
NCT07484243RecruitingRheumatoid Arthritis (RA) | Rheumatoid Arthritis-Associated Interstitial Lung Disease | Difficult-to-Treat Rheumatoid Arthritis
-
NCT03781375Terminated
-
NCT00000429CompletedJuvenile Rheumatoid Arthritis
-
NCT00078793CompletedJuvenile Rheumatoid Arthritis
-
NCT03062865RecruitingRheumatoId Arthritis
-
NCT02997605Completed
-
NCT02585258CompletedRheumatoId Arthritis
Clinical Trials on observational study
-
NCT06157723RecruitingKnee Osteoarthritis
-
NCT01836315CompletedObesity | Pregnancy | Cesarean Section
-
NCT03600675Completed
-
NCT07456436RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System Neoplasm
-
NCT07439471RecruitingCigarette Smoking-Related Carcinoma
-
NCT07412002Not yet recruitingChildhood Hematopoietic and Lymphatic System Neoplasm | Childhood Malignant Solid Neoplasm
-
NCT07341503RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma
-
NCT07306338RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System Neoplasm
-
NCT07279571RecruitingEndometrial Carcinoma